Pregabalin Capsule
Product Images NDC 71610-925

Product Visual Gallery

This gallery contains 15 technical images submitted to the FDA as part of the official labeling for Pregabalin (NDC 71610-925). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Aphena Pharma Solutions - Tennessee, Llc, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

FDA Label Image

Label (71610 0925 30)

This is a product label for pregabalin, which is indicated for the treatment of seizures, neuropathic pain, and fibromyalgia. The NDC number provided is 71610-925-30.*

FDA Label Image

Aphena (Aphena)

FDA Label Image

Chemical Structure (Pregabalin 01)

FDA Label Image

Figure 1 (Pregabalin 02)

FDA Label Image

Figure 2 (Pregabalin 03)

FDA Label Image

Figure 3 (Pregabalin 04)

FDA Label Image

Figure 4 (Pregabalin 05)

Percent of Patients Improved: This text appears to show data related to the improvement of patients based on different treatments. The data seems to include information on the improvement of patients taking Pregabain at different dosages and frequencies and those taking a placebo. The chart may also depict the percentage improvement in pain from a baseline measurement.*

FDA Label Image

Figure 5 (Pregabalin 06)

FDA Label Image

Figure 6 (Pregabalin 07)

FDA Label Image

Figure 7 (Pregabalin 08)

FDA Label Image

Figure 8 (Pregabalin 09)

This text provides information on response rates for different treatments, including placebo and two doses of 2.5 mg/kg/day and 10 mg/kg/day. The responder rates are shown as percentages, with values of 60%, 50%, 22.6%, and 29.1%. This data could be used to compare the effectiveness of the treatments in a study or clinical trial.*

FDA Label Image

Figure 9 (Pregabalin 10)

FDA Label Image

Figure 10 (Pregabalin 11)

FDA Label Image

Figure 11 (Pregabalin 12)

This text mentions the percentage of subjects that improved from baseline to week 12 in a study involving the drug Pregabalin. It indicates that 90-100% of subjects showed improvement. The data is presented across multiple values ranging from 0 to 280.*

FDA Label Image

Figure 12 (Pregabalin 13)

* These product label images have been analyzed using experimental machine learning. Please verify findings with the primary label text.